Vanda Pharmaceuticals Inc.
VNDAHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. Valued at $327.1M, VNDA is a small-cap name in its sector. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Market Cap
$327.1M
Beta
0.60
P/E (TTM)
—
P/E (Fwd)
27.20
EPS (TTM)
$-4.05
EPS (Fwd)
$0.20
ROE
-60.5%
ROA
-18.8%
Cash
$202.3M
Total Debt
$13.1M
Free CF
-$83.2M
52W Change
13.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $202.3M in cash comfortably exceeding the $13.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$83.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -60.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $254.4M to $216.1M.
With a beta below 0.7, Vanda Pharmaceuticals Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Vanda Pharmaceuticals Inc. and its sector.